In this segment of the weekly health-care show, analyst David Williamson explains why investors need to have Arena Pharmaceuticals (NASDAQ:ARNA) on their radar. Watch and find out how a big EU approval decision, DEA scheduling, and the first quarter sales report of competitor Vivus's (NASDAQ:VVUS) Qsymia could impact the stock in the coming weeks.
Dave Williamson, Brenton Flynn, and Max Macaluso
Apr 12, 2013 at 6:23PM
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings... Follow @motleydavid
Motley Fool Returns
Stock Advisor S&P 500
Stock Advisor launched in February of 2002. Returns as of 06/06/2020.Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return